Literature DB >> 31200861

Monitoring and deciphering protein degradation pathways inside cells.

Danette L Daniels1, Kristin M Riching2, Marjeta Urh2.   

Abstract

A new series of therapeutic modalities resulting in degradation of target proteins, termed proteolysis targeting chimeras (PROTACs), hold significant therapeutic potential with possible prolonged pharmacodynamics, improved potency, and ability to target proteins previously thought of as "undruggable". PROTACs are heterobifunctional small molecules consisting of a target binding handle bridged via a chemical linker to an E3 ligase handle which recruit the E3 ligase and ubiquitin machinery to target proteins, resulting in subsequent ubiquitination and degradation of the target. With the generation of small molecule PROTAC compound libraries for drug discovery, it becomes essential to have sensitive screening technologies to rapidly profile activity and have assays which can clearly inform on performance at the various cellular steps required for PROTAC-mediated degradation. For PROTAC compounds, this has been particularly challenging using either biochemical or cellular assay approaches. Biochemical assays are highly informative for the first part of the degradation process, including optimization of compound binding to targets and interrogation of target:PROTAC:E3 ligase ternary complex formation, but struggle with the remaining steps; recruitment of ternary complex into larger active E3 ligase complexes, ubiquitination, and proteasomal degradation. On the other hand, cellular assays are excellent at determining if the PROTAC successfully degrades the target in its relevant setting but struggle as early development PROTAC compounds are often poorly cell-permeable given their high molecular weight. Additionally, if degradation is not observed in a cellular assay, it is difficult to deconvolute the reason why or at which step there was failure. In this review we will highlight the current approaches along with recent advances to overcome the challenges faced for cellular PROTAC screening, which will enable and advance drug discovery of therapeutic degradation compounds.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Mesh:

Substances:

Year:  2018        PMID: 31200861     DOI: 10.1016/j.ddtec.2018.12.001

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  16 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

2.  Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.

Authors:  Caroline A Foley; Frances Potjewyd; Kelsey N Lamb; Lindsey I James; Stephen V Frye
Journal:  ACS Chem Biol       Date:  2019-12-27       Impact factor: 5.100

3.  A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET.

Authors:  James D Vasta; Cesear R Corona; Matthew B Robers
Journal:  Methods Mol Biol       Date:  2021

4.  Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.

Authors:  Sarah D Mahan; Kristin M Riching; Marjeta Urh; Danette L Daniels
Journal:  Methods Mol Biol       Date:  2021

Review 5.  PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.

Authors:  Jyotsana Madan; Vijay Kamal Ahuja; Kamal Dua; Susanta Samajdar; Murali Ramchandra; Sanjeev Giri
Journal:  BioDrugs       Date:  2022-09-13       Impact factor: 7.744

Review 6.  Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.

Authors:  Fabian Krutzek; Klaus Kopka; Sven Stadlbauer
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

7.  Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.

Authors:  Charles E Hendrick; Jeff R Jorgensen; Charu Chaudhry; Iulia I Strambeanu; Jean-Francois Brazeau; Jamie Schiffer; Zhicai Shi; Jennifer D Venable; Scott E Wolkenberg
Journal:  ACS Med Chem Lett       Date:  2022-06-20       Impact factor: 4.632

Review 8.  Assays and technologies for developing proteolysis targeting chimera degraders.

Authors:  Xingui Liu; Xuan Zhang; Dongwen Lv; Yaxia Yuan; Guangrong Zheng; Daohong Zhou
Journal:  Future Med Chem       Date:  2020-05-20       Impact factor: 3.808

Review 9.  Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective.

Authors:  Laura M Luh; Ulrike Scheib; Katrin Juenemann; Lars Wortmann; Michael Brands; Philipp M Cromm
Journal:  Angew Chem Int Ed Engl       Date:  2020-07-30       Impact factor: 15.336

Review 10.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.